相关实验视频

Updated: May 25, 2025

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

用奥林克蛋白质组学识别急性心肌梗塞的心脏代谢蛋白生物标志物

Xin Tan^1,2, Xiangyu Wang^1,2, Shuai Xu^1,2

¹Department of Cardiology, the Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzhou, 215000, People's Republic of China.

Journal of inflammation research

|February 27, 2025

概括

这项研究确定了五种核心蛋白质 (PCOLCE,FCN2,REG1A,DEFA1,CRTAC1) 作为早期急性心肌梗塞 (AMI) 诊断和风险评估的潜在生物标志物. 这些发现可能会导致心血管代谢损伤的新治疗点.

科学领域:

心血管代谢的代谢学.
发现生物标志物的发现.
分子诊断学分子诊断学

背景情况:

急性心肌梗塞 (AMI) 是一个关键的心血管事件,对其相关的代谢损伤的理解有限.
目前针对AMI的诊断和治疗策略需要改进,特别是在早期检测和有针对性的治疗方面.
识别特定的蛋白质生物标志物对于解决早期AMI诊断和个性化治疗的临床需求至关重要.

研究的目的:

探索与AMI相关的与心血管代谢相关的蛋白质生物标志物,使用奥林克心血管代谢学技术.
为早期诊断和AMI风险评估确定新的蛋白质标.
调查 AMI 治疗干预的已识别的生物标志物的潜力.

主要方法:

奥林克心血管代谢学被用来分析20名AMI患者和10名对照者的冠状动脉血液中的92种蛋白质.
统计分析确定了差异表达的蛋白质,其次是功能丰富和蛋白质-蛋白质相互作用网络分析.
在血中验证了五种核心蛋白,并使用孟德尔随机化评估了它们与AMI风险的因果关系.

主要成果:

与对照组相比,在AMI患者中,32种蛋白质的表达显著改变.
确定了五种核心蛋白质 (PCOLCE,FCN2,REG1A,DEFA1,CRTAC1),它们与新陈代谢,原蛋白形成和PI3K/AKT信号传递有关.
FCN2和DEFA1与AMI风险存在因果关系,突出了它们的诊断潜力.

结论:

已识别的核心蛋白质 (PCOLCE,FCN2,REG1A,DEFA1,CRTAC1) 显示为早期AMI诊断和风险分层的生物标志物具有前途.
这些蛋白质可以作为新型治疗策略的标,旨在减轻AMI患者的心血管代谢损伤.
对这些生物标志物的进一步研究可以显著提高AMI管理和患者的治疗结果.

关键词:

奥林克的蛋白质组学剧烈的心肌梗塞急性心肌梗塞生物标志物生物标志物心血管代谢组的代谢组.

更多相关视频

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Proteomics

Proteomics

A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...